Xiaosha Zhang

666 total citations
22 papers, 481 citations indexed

About

Xiaosha Zhang is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaosha Zhang has authored 22 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 13 papers in Genetics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaosha Zhang's work include Hemoglobinopathies and Related Disorders (11 papers), Blood groups and transfusion (7 papers) and Acute Myeloid Leukemia Research (6 papers). Xiaosha Zhang is often cited by papers focused on Hemoglobinopathies and Related Disorders (11 papers), Blood groups and transfusion (7 papers) and Acute Myeloid Leukemia Research (6 papers). Xiaosha Zhang collaborates with scholars based in United States, Germany and Greece. Xiaosha Zhang's co-authors include Kenneth M. Attie, Matthew L. Sherman, Abderrahmane Laadem, Philipp Kiewe, Markus P. Radsak, Aristoteles Giagounidis, Katharina S. Götze, Uwe Platzbecker, Karin Mayer and Thomas Wolff and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Xiaosha Zhang

21 papers receiving 474 citations

Peers

Xiaosha Zhang
Comparison fields: 5 of 47
  • Hematology 359
  • Genetics 288
  • Molecular Biology 138
  • Physiology 56
  • Pulmonary and Respiratory Medicine 51
Arjan van de Loosdrecht Netherlands
Tiejun Qin China
Ilaria Ambaglio Italy
Alexander J. Silver United States
Rosa Marı́a Arana-Trejo Mexico
Judith Neukirchen Germany
Neng Nie China
Carlos Hader United States
Heather A. Bradeen United States
Marcio Andrade‐Campos Spain
Arjan van de Loosdrecht Netherlands View profile →
Citations per field, relative to Xiaosha Zhang
Xiaosha Zhang · 1×
Citations per year, relative to Xiaosha Zhang
Xiaosha Zhang · 1×

Countries citing papers authored by Xiaosha Zhang

Since Specialization
Citations

This map shows the geographic impact of Xiaosha Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaosha Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaosha Zhang more than expected).

Fields of papers citing papers by Xiaosha Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaosha Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaosha Zhang. The network helps show where Xiaosha Zhang may publish in the future.

Co-authorship network of co-authors of Xiaosha Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaosha Zhang. A scholar is included among the top collaborators of Xiaosha Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaosha Zhang. Xiaosha Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension
2024 ·Pulmonary Circulation ·Hunter Gillies, Murali M. Chakinala, Benjamin T. Dake, Jeremy P. Feldman, Marius M. Hoeper, Marc Humbert, Zhi‐Cheng Jing, Jonathan Langley, Vallerie V. McLaughlin, Ralph W. Niven, Stephan Rosenkranz, Xiaosha Zhang, Nicholas S. Hill
5
2
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
2022 ·Therapeutic Advances in Hematology ·Antonio Piga, Filomena Longo, Maria Rita Gamberini, Ersi Voskaridou, Paolo Ricchi, Vincenzo Caruso, Antonello Pietrangelo, Xiaosha Zhang, Jeevan K. Shetty, Kenneth M. Attie, Immacolata Tartaglione
13
3
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
2022 ·Journal of Clinical Oncology ·Uwe Platzbecker, Katharina S. Götze, Philipp Kiewe, Ulrich Germing, Karin Mayer, Markus P. Radsak, Thomas Wolff, (unknown), Katja Sockel, Uta Oelschlägel, Detlef Haase, Thomas Illmer, Haifa Kathrin Al‐Ali, Gerda Silling, Joseph G. Reynolds, Xiaosha Zhang, Kenneth M. Attie, Jeevan K. Shetty, Aristoteles Giagounidis
19
4
MDS-191: Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study
2020 ·Clinical Lymphoma Myeloma & Leukemia ·Uwe Platzbecker, Philipp Kiewe, Ulrich Germing, Katharina S. Götze, Karin Mayer, Markus P. Radsak, Thomas Wolff, (unknown), Joseph G. Reynolds, (unknown), Xiaosha Zhang, Abderrahmane Laadem, Kenneth M. Attie, Aristoteles Giagounidis
0
5
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
2019 ·Cancer ·Martin H. Voss, Rupal S. Bhatt, Nicholas J. Vogelzang, Mayer Fishman, Robert Alter, Brian I. Rini, J. Thaddeus Beck, Monika Joshi, Ralph J. Hauke, Michael B. Atkins, Earle F. Burgess, Theodore F. Logan, David R. Shaffer, Rahul Atul Parikh, (unknown), Xiaosha Zhang, Chad Glasser, Matthew L. Sherman, Elizabeth R. Plimack
21
6
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia
2019 ·Blood ·Antonio Piga, Silverio Perrotta, Maria Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Aldo Filosa, Vincenzo Caruso, Antonello Pietrangelo, Filomena Longo, Immacolata Tartaglione, Caterina Borgna‐Pignatti, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie
82
7
Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©)
2018 ·American Journal of Hematology ·Alì Taher, Vip Viprakasit, Maria Domenica Cappellini, Pranee Sutcharitchan, Richard Ward, Dalia Mahmoud, Abderrahmane Laadem, Anzalee Khan, Chad Gwaltney, Gale Harding, Kenneth M. Attie, Xiaosha Zhang, Jun Zou, (unknown), (unknown), Antonis Kattamis
6
8
Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©)
2018 ·American Journal of Hematology ·Alì Taher, Maria Domenica Cappellini, Vip Viprakasit, Pranee Sutcharitchan, Dalia Mahmoud, Abderrahmane Laadem, Anzalee Khan, Chad Gwaltney, Gale Harding, Kenneth M. Attie, Xiaosha Zhang, Jun Zou, (unknown), (unknown), Antonis Kattamis
6
9
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
2017 ·The Lancet Oncology ·Uwe Platzbecker, Ulrich Germing, Katharina S. Götze, Philipp Kiewe, Karin Mayer, Jörg Chromik, Markus P. Radsak, Thomas Wolff, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie, Aristoteles Giagounidis
204
10
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
2016 ·Clinical Cancer Research ·Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, (unknown), Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Shuchi S. Pandya, Michael B. Atkins
21
11
A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
2016 ·Cancer ·Antonio Jimeno, Marshall R. Posner, Lori J. Wirth, Nabil F. Saba, Roger B. Cohen, E Popa, Athanassios Argiris, Kenneth F. Grossmann, Ammar Sukari, Dawn Wilson, Xiaosha Zhang, (unknown), Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, (unknown), Jared Weiss
28
12
Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies
2016 ·Blood ·Nianhang Chen, Abderrahmane Laadem, Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, S Ritland, Kenneth M. Attie
8
13
Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia
2016 ·Blood ·Antonio Piga, Immacolata Tartaglione, Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Paolo Ricchi, Vincenzo Caruso, Antonello Pietrangelo, Xiaosha Zhang, Dawn Wilson, (unknown), Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie
13
14
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study
2016 ·Blood ·Uwe Platzbecker, Ulrich Germing, Katharina S. Götze, Philipp Kiewe, Thomas Wolff, Karin Mayer, (unknown), Markus P. Radsak, (unknown), Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie, Aristoteles Giagounidis
11
15
Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study
2015 ·Blood ·Aristoteles Giagounidis, Uwe Platzbecker, Ulrich Germing, Katharina S. Götze, Philipp Kiewe, Karin Mayer, Oliver G. Ottmann, Markus P. Radsak, Thomas Wolff, Detlef Haase, (unknown), Dawn Wilson, Xiaosha Zhang, (unknown), Matthew L. Sherman, Kenneth M. Attie
22
16
DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1.
2015 ·Journal of Clinical Oncology ·Martin H. Voss, Elizabeth R. Plimack, Brian I. Rini, Michael B. Atkins, Robert Alter, Rupal S. Bhatt, J. Thaddeus Beck, (unknown), Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi S. Pandya
2
17
Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study
2015 ·Blood ·Antonio Piga, Silverio Perrotta, Maria Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Aldo Filosa, Antonello Pietrangelo, Vincenzo Caruso, Gian Luca Forni, Xiaosha Zhang, (unknown), Dawn Wilson, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie
7
18
Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
2015 ·Blood ·Uwe Platzbecker, Ulrich Germing, Aristoteles Giagounidis, Katharina S. Götze, Philipp Kiewe, Karin Mayer, Oliver G. Ottmann, Markus P. Radsak, Thomas Wolff, Detlef Haase, (unknown), Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie
5
19
The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC).
2015 ·Journal of Clinical Oncology ·Martin H. Voss, Elizabeth R. Plimack, Brian I. Rini, Michael B. Atkins, Robert Alter, Rupal S. Bhatt, J. Thaddeus Beck, (unknown), (unknown), Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi S. Pandya
1
20
Methods of designing two‐stage winner trials with survival outcomes
2013 ·Statistics in Medicine ·Fang Fang, Yong Lin, Weichung Joe Shih, Yulin Li, (unknown), Xiaosha Zhang
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arjan van de Loosdrecht Breakdown of academic impact, for papers by Tiejun Qin Breakdown of academic impact, for papers by Ilaria Ambaglio Breakdown of academic impact, for papers by Alexander J. Silver Breakdown of academic impact, for papers by Rosa Marı́a Arana-Trejo Breakdown of academic impact, for papers by Judith Neukirchen Breakdown of academic impact, for papers by Neng Nie Breakdown of academic impact, for papers by Carlos Hader Breakdown of academic impact, for papers by Heather A. Bradeen Breakdown of academic impact, for papers by Marcio Andrade‐Campos
Rankless by CCL
2026